- Home
- PRFX vs NCNA Comparison
PRFX vs NCNA Comparison
Compare PRFX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- NCNA
- Stock Information
- Founded
- PRFX 2007
- NCNA 1997
- Country
- PRFX Israel
- NCNA United Kingdom
- Employees
- PRFX N/A
- NCNA N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- NCNA Health Care
- Exchange
- PRFX Nasdaq
- NCNA Nasdaq
- Market Cap
- PRFX 3.0M
- NCNA 3.4M
- IPO Year
- PRFX 2020
- NCNA 2017
- Fundamental
- Price
- PRFX $2.30
- NCNA $0.97
- Analyst Decision
- PRFX Hold
- NCNA Buy
- Analyst Count
- PRFX 1
- NCNA 2
- Target Price
- PRFX N/A
- NCNA $25.00
- AVG Volume (30 Days)
- PRFX 46.2K
- NCNA 118.8K
- Earning Date
- PRFX 01-01-0001
- NCNA 05-15-2025
- Dividend Yield
- PRFX N/A
- NCNA N/A
- EPS Growth
- PRFX N/A
- NCNA N/A
- EPS
- PRFX N/A
- NCNA N/A
- Revenue
- PRFX N/A
- NCNA N/A
- Revenue This Year
- PRFX N/A
- NCNA N/A
- Revenue Next Year
- PRFX N/A
- NCNA N/A
- P/E Ratio
- PRFX N/A
- NCNA N/A
- Revenue Growth
- PRFX N/A
- NCNA N/A
- 52 Week Low
- PRFX $0.43
- NCNA $0.69
- 52 Week High
- PRFX $16.63
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- PRFX 36.25
- NCNA 48.38
- Support Level
- PRFX $2.12
- NCNA $0.81
- Resistance Level
- PRFX $2.79
- NCNA $1.34
- Average True Range (ATR)
- PRFX 0.17
- NCNA 0.14
- MACD
- PRFX -0.04
- NCNA 0.02
- Stochastic Oscillator
- PRFX 21.69
- NCNA 29.20
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.